PHS
RYTM icon

PFM Health Sciences’s Rhythm Pharmaceuticals RYTM Stock Holding History

PFM Health Sciences’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9M Buy
136,621
+96,411
+240% +$9.38M 1.08% 30
2025
Q4 		$4.3M Sell
40,210
-7,952
-17% -$844K 0.43% 56
2025
Q3 		$4.86M Buy
+48,162
New +$4.47M 0.37% 50

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

PFM Health Sciences's RYTM Position: Q1 2026 in Review

PFM Health Sciences increased its Rhythm Pharmaceuticals (RYTM) stake by 240% in Q1 2026, buying an estimated $9.38M and bringing the position to 136,621 shares worth $11.9M. The position accounts for 1.08% of the portfolio, ranked #30.

PFM Health Sciences first reported a position in RYTM in Q3 2025 and has held it in 3 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • PFM Health Sciences held 136,621 shares of Rhythm Pharmaceuticals worth $11.9M as of Q1 2026.
  • PFM Health Sciences bought 96,411 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $9.38M.
  • Rhythm Pharmaceuticals made up 1.08% of PFM Health Sciences's portfolio in Q1 2026, its #30 holding.
  • PFM Health Sciences first reported a position in Rhythm Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.